Matt van de Rijn

Matt van de Rijn

Auto-generated profile, based on publicly available information

Matt van de Rijn

Department of Pathology, Stanford University, Stanford, California

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2006 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
RWRobert B. West
Robert B. West
BRBrian P. Rubin
Brian P. Rubin
MMMelinda A. Miller
Melinda A. Miller
Subbaya SubramanianSubbaya Subramanian
Subbaya Subramanian
GKGulsah Kaygusuz
Gulsah Kaygusuz
MRMatt van de Rijn
Matt van de Rijn
Tenosynovial giant-cell tumor (TGCT) and pigmented villonodular synovitis (PVNS) are related conditions with features of both reactive inflammatory disorders and clonal neoplastic proliferations. Chromosomal translocations involving chromosome 1p13 have been reported in both TGCT and PVNS. We confirm that translocations involving 1p13 are present in a majority of cases of TGCT and PVNS and show that CSF1 is the gene at the chromosome 1p13 breakpoint. In some cases of both TGCT and PVNS, CSF1 is fused to COL6A3 (2q35). The CSF1 translocations result in overexpression of CSF1 . In cases of TGCT and PVNS carrying this translocation, it is present in a minority of the intratumoral cells, leading to CSF1 expression only in these cells, whereas the majority of cells express CSF1R but not CSF1 , suggesting a tumor-landscaping effect with aberrant CSF1 expression in the neoplastic cells, leading to the abnormal accumulation of nonneoplastic cells that form a tumorous mass.

1 December 2002 in The American Journal of Pathology
Verified
Journal Article
Closed access
MRMatt van de Rijn
Matt van de Rijn
CPCharles M Perou
Charles M Perou
RTRob Tibshirani
Rob Tibshirani
PHPhillippe Haas
Phillippe Haas
OKOlli Kallioniemi
Olli Kallioniemi
PBPat Brown
Pat Brown

30 September 2021 in Cell
Verified
Journal Article
Closed access
BLBogdan A. Luca
Bogdan A. Luca
CSChloé B. Steen
Chloé B. Steen
MMMagdalena Matusiak
Magdalena Matusiak
AAArmon Azizi
Armon Azizi
SVSushama Varma
Sushama Varma
ANAaron M. Newman
Aaron M. Newman

28 August 2012 in Genome Biology
Verified
Journal Article
Open access
PDF file
ABAlayne L Brunner
Alayne L Brunner
ABAndrew H Beck
Andrew H Beck
BEBadreddin Edris
Badreddin Edris
RSRobert T Sweeney
Robert T Sweeney
SZShirley X Zhu
Shirley X Zhu
RWRobert B. West
Robert B. West
Background: Molecular characterization of tumors has been critical for identifying important genes in cancer biology and for improving tumor classification and diagnosis. Long non-coding RNAs, as a new, relatively unstudied class of transcripts, provide a rich opportunity to identify both functional drivers and cancer-type-specific biomarkers. However, despite the potential importance of long non-coding RNAs to the cancer field, no comprehensive survey of long non-coding RNA expression across various cancers has been reported. Results: We performed a sequencing-based transcriptional survey of both known long non-coding RNAs and novel intergenic transcripts across a panel of 64 archival tumor samples comprising 17 diagnostic subtypes of adenocarcinomas, squamous cell carcinomas and sarcomas. We identified hundreds of transcripts from among the known 1,065 long non-coding RNAs surveyed that showed variability in transcript levels between the tumor types and are therefore potential biomarker candidates. We discovered 1,071 novel intergenic transcribed regions and demonstrate that these show similar patterns of variability between tumor types. We found that many of these differentially expressed cancer transcripts are also expressed in normal tissues. One such novel transcript specifically expressed in breast tissue was further evaluated using RNA in situ hybridization on a panel of breast tumors. It was shown to correlate with low tumor grade and estrogen receptor expression, thereby representing a potentially important new breast cancer biomarker. Conclusions: This study provides the first large survey of long non-coding RNA expression within a panel of solid cancers and also identifies a number of novel transcribed regions differentially expressed across distinct cancer types that represent candidate biomarkers for future research.

26 March 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
BEBadreddin Edris
Badreddin Edris
KWKipp Weiskopf
Kipp Weiskopf
AVAnne K. Volkmer
Anne K. Volkmer
JVJens-Peter Volkmer
Jens-Peter Volkmer
SWStephen B. Willingham
Stephen B. Willingham
MRMatt van de Rijn
Matt van de Rijn
Antibodies against CD47, which block tumor cell CD47 interactions with macrophage signal regulatory protein-α, have been shown to decrease tumor size in hematological and epithelial tumor models by interfering with the protection from phagocytosis by macrophages that intact CD47 bestows upon tumor cells. Leiomyosarcoma (LMS) is a tumor of smooth muscle that can express varying levels of colony-stimulating factor-1 (CSF1), the expression of which correlates with the numbers of tumor-associated macrophages (TAMs) that are found in these tumors. We have previously shown that the presence of TAMs in LMS is associated with poor clinical outcome and the overall effect of TAMs in LMS therefore appears to be protumorigenic. However, the use of inhibitory antibodies against CD47 offers an opportunity to turn TAMs against LMS cells by allowing the phagocytic behavior of resident macrophages to predominate. Here we show that interference with CD47 increases phagocytosis of two human LMS cell lines, LMS04 and LMS05, in vitro. In addition, treatment of mice bearing subcutaneous LMS04 and LMS05 tumors with a novel, humanized anti-CD47 antibody resulted in significant reductions in tumor size. Mice bearing LMS04 tumors develop large numbers of lymph node and lung metastases. In a unique model for neoadjuvant treatment, mice were treated with anti-CD47 antibody starting 1 wk before resection of established primary tumors and subsequently showed a striking decrease in the size and number of metastases. These data suggest that treatment with anti-CD47 antibodies not only reduces primary tumor size but can also be used to inhibit the development of, or to eliminate, metastatic disease.

27 March 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
MMMagdalena Matusiak
Magdalena Matusiak
JHJohn W. Hickey
John W. Hickey
DIDavid G.P. van Ijzendoorn
David G.P. van Ijzendoorn
GLGuolan Lu
Guolan Lu
LKLukasz Kidziński
Lukasz Kidziński
MRMatt van de Rijn
Matt van de Rijn
Tumor-associated macrophages are transcriptionally heterogeneous, but the spatial distribution and cell interactions that shape macrophage tissue roles remain poorly characterized. Here, we spatially resolve five distinct human macrophage populations in normal and malignant human breast and colon tissue and reveal their cellular associations. This spatial map reveals that distinct macrophage populations reside in spatially segregated micro-environmental niches with conserved cellular compositions that are repeated across healthy and diseased tissue. We show that IL4I1+ macrophages phagocytose dying cells in areas with high cell turnover and predict good outcome in colon cancer. In contrast, SPP1+ macrophages are enriched in hypoxic and necrotic tumor regions and portend worse outcome in colon cancer. A subset of FOLR2+ macrophages is embedded in plasma cell niches. NLRP3+ macrophages co-localize with neutrophils and activate an inflammasome in tumors. Our findings indicate that a limited number of unique human macrophage niches function as fundamental building blocks in tissue. Significance: This work broadens our understanding of the distinct roles different macrophage populations may exert on cancer growth and reveals potential predictive markers and macrophage population-specific therapy targets.